Novartis wins Supreme Court temporary reprieve on Gilenya generics (NYSE:NVS)
The Supreme Court on Wednesday agreed with Novartis to stay a mandate from an appeals court that would have allowed generics of the its blockbuster multiple sclerosis drug Gilenya.
Novartis wins Supreme Court temporary reprieve on Gilenya generics (NYSE:NVS)
The Supreme Court on Wednesday agreed with Novartis to stay a mandate from an appeals court that would have allowed generics of the its blockbuster multiple sclerosis drug Gilenya.